ArticlePsychopharmacology2026
Galantamine as add-on therapy to escitalopram: enhancing antidepressant therapeutic potential via. Targeting α7nAChR/BDNF/KYN signalling.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
rationaleMajor depressive disorder (MDD) is a significant global health issue, yet its pathophysiology remains unclear. One-third of patients achieve complete remission with monotherapy, highlighting the need for effective add-on therapies.
objectivesThis study explores the antidepressant potential of galantamine (GAL) as an add-on to escitalopram (ESC), focusing on the neurotrophic system, kynurenine pathway, neuroinflammation, and oxidative stress in MDD.
methodsWe employed corticosterone (CORT)-induced toxicity in Neuro-2a cells and an unpredictable chronic mild stress (UCMS) model in mice to simulate depressive conditions. Neuro-2a cells were treated with GAL (39 µM) and ESC (107 µM) in CORT pretreated cells to better understand the protective potential of the drug combination. In vivo treatment with GAL (3 and 5 mg/kg) and ESC (5 and 10 mg/kg) for four weeks in UCMS mice was evaluated for behavioural, biochemical, and histopathological changes.
resultsThe combination therapy enhanced cell viability, reduced apoptosis, and lowered intracellular ROS levels in Neuro-2a cells. In vivo, treatment with the GAL + ESC combination significantly alleviated UCMS-induced depressive symptoms and improved working memory. The combined therapy modulated the brain-derived neurotrophic factor (BDNF), 3-hydroxykynurenine (3-HK), quinolinic acid (QUIN), TNF-α, and IL-6 levels, reversing oxidative stress markers in the hippocampus. Moreover, the combined therapy preserved hippocampal structure and modulated α7 nicotinic acetylcholine receptor (α7nAChR) density in the CA1 region of the hippocampus.
conclusionsThis study signifies the potential of GAL as an add-on therapy to ESC, enhancing antidepressant effects and cognitive function, warranting further clinical investigation for treating depressive disorders.
Indexed as
Identifiers
40576678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.